Precision Medicine

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A new study reveals an 'early warning system' in infant guts, offering a window to combat the atopic march before allergies take hold. Is this the future?

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

Origin Agritech's gene-editing breakthrough allows corn to mature faster without sacrificing yield, a holy grail for breeders and a boon for global food security.

A new study reveals molecular and AI-imaging tests provide distinct clues for Parkinson's, championing a dual-biomarker approach for earlier, more accurate diagnosis.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

A Japanese firm has achieved a breakthrough in manufacturing ultra-smooth capillary tubes, a tiny component set to unlock major advances in medicine and tech.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.